Evidence map›Paper›PMID 29671020›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2018

Luteolin alleviates cardiac ischemia/reperfusion injury in the hypercholesterolemic rat via activating Akt/Nrf2 signaling.

Jin-Ting Yang, Jue Wang, Xin-Ru Zhou, Chi Xiao, Yang-Yun Lou, Li-Hui Tang, Feng-Jiang Zhang, Ling-Bo Qian

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jin-Ting YangDepartment of Anesthesiology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Jue WangDepartment of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, 481 Binwen Road, Hangzhou, 310053, China.
Xin-Ru ZhouDepartment of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, 481 Binwen Road, Hangzhou, 310053, China.
Chi XiaoDepartment of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, 481 Binwen Road, Hangzhou, 310053, China.
Yang-Yun LouDepartment of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, 481 Binwen Road, Hangzhou, 310053, China.
Li-Hui TangDepartment of Anesthesiology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Feng-Jiang ZhangDepartment of Anesthesiology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
Ling-Bo QianDepartment of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, 481 Binwen Road, Hangzhou, 310053, China. bioqian@163.com.

Funding

Chinese Medicine Research Program of Zhejiang Province 2016ZA045National Natural Science Foundation of China 81600203National Natural Science Foundation of China 81671883National Natural Science Foundation of China 81772035Science and Technology Department of Zhejiang Province 2016C37133
6 · The paper itself

Abstract

Myocardial ischemia/reperfusion (I/R) injury in hypercholesterolemia is associated with oxidative stress, while luteolin is known to reduce oxidative stress by activating Akt/nuclear factor erythroid-2-related factor 2 (Nrf2) signaling and alleviate cardiac I/R injury. Here, we investigated whether luteolin pretreatment diminishes myocardial I/R injury in hypercholesterolemic rats by activating Akt/Nrf2 signaling. Hypercholesterolemic rats were produced by 2% cholesterol diet for 8 weeks. Luteolin (100 mg/kg/day, i.g.) or LY294002 was administered for the last 2 weeks. The hearts were then isolated and subjected to 30 min of global ischemia followed by 120 min of reperfusion. Pretreatment with luteolin significantly improved left ventricular function throughout reperfusion, increased cardiac tissue viability, reduced coronary lactate dehydrogenase release and the myocardial malondialdehyde level, upregulated p-Akt and p-GSK3β expressions, inhibited nuclear translocation of Fyn, and activated Nrf2 function in hypercholesterolemic I/R rat hearts. All these improving effects of luteolin were significantly attenuated by LY294002. Ca

Indexed as

AnimalsCardiotonic AgentsHypercholesterolemiaLuteolinMaleMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreMyocardial Reperfusion InjuryNF-E2-Related Factor 2Proto-Oncogene Proteins c-aktRatsRats, Sprague-DawleySignal TransductionCardiotonic AgentsLuteolinMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreNF-E2-Related Factor 2Proto-Oncogene Proteins c-aktAktHypercholesterolemiaLuteolinMyocardial ischemia/reperfusion injuryNrf2Oxidative stress

Identifiers

PMID29671020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.